The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Thetis cells, a class of immune cells first described in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

Actemra has possible interactions with some other drugs. Examples include atorvastatin and warfarin. Talk with your doctor to ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in 2017, according ...

The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA). The approval was based on data ...

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial ...

Traumatic brain injury (TBI). Merck Manual Professional Edition. Giant cell arteritis. Watanabe A, Isono H, Shimada K, Chino Y. A typical case of giant cell arteritis with vision loss due to delayed ...